[{"id":"60497dbb-56e8-4c40-973c-67ee89c74186","acronym":"","url":"https://clinicaltrials.gov/study/NCT06890585","created_at":"2025-09-07T02:05:51.287Z","updated_at":"2025-09-07T02:05:51.287Z","phase":"Phase 2","brief_title":"Zanubrutinib, Chidamide, and Rituximab Induction with or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","source_id_and_acronym":"NCT06890585","lead_sponsor":"Li Zhiming","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-24"},{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"3272fb35-7910-45fd-a4ab-4ef1f176f237","acronym":"BGB-3111-218","url":"https://clinicaltrials.gov/study/NCT05068440","created_at":"2021-10-05T20:00:21.125Z","updated_at":"2025-02-25T12:38:01.088Z","phase":"Phase 2","brief_title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","source_id_and_acronym":"NCT05068440 - BGB-3111-218","lead_sponsor":"BeiGene","biomarkers":" CD79B","pipe":" | ","alterations":" CD79B mutation • CD79B mutation","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-24"},{"id":"85055237-577b-4c03-b564-e7f118cc30e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06637501","created_at":"2025-02-25T14:11:41.845Z","updated_at":"2025-02-25T14:11:41.845Z","phase":"Phase 2","brief_title":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT06637501","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 11/14/2024","start_date":" 11/14/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"},{"id":"d47210cd-de05-419e-be0b-3ae8833c707d","acronym":"BGB-11417-108","url":"https://clinicaltrials.gov/study/NCT06697184","created_at":"2025-02-25T14:05:04.300Z","updated_at":"2025-02-25T14:05:04.300Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","source_id_and_acronym":"NCT06697184 - BGB-11417-108","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/23/2025","start_date":" 01/23/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"4ae271df-843f-4292-9867-8d901b35d784","acronym":"PIPOZA","url":"https://clinicaltrials.gov/study/NCT06812715","created_at":"2025-02-25T16:42:55.747Z","updated_at":"2025-02-25T16:42:55.747Z","phase":"Phase 2","brief_title":"Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated with Pirtobrutinib After Previous Treatment with Zanubrutinib","source_id_and_acronym":"NCT06812715 - PIPOZA","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BTK","pipe":"","alterations":" ","tags":["BTK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2031","study_completion_date":" 05/01/2031","last_update_posted":"2025-02-06"},{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"BGB-3111-402","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2025-02-25T17:02:16.646Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102 - BGB-3111-402","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"},{"id":"99c5ce8b-5c38-453f-ad28-f12ae4fd578b","acronym":"BGB-11417-203","url":"https://clinicaltrials.gov/study/NCT05952037","created_at":"2023-07-20T14:08:47.056Z","updated_at":"2025-02-25T17:39:02.716Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05952037 - BGB-11417-203","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-01-29"},{"id":"731a7f94-ad73-4cc1-96c6-298d3b4cf270","acronym":"ZEBRA","url":"https://clinicaltrials.gov/study/NCT05635162","created_at":"2022-12-02T15:56:31.374Z","updated_at":"2024-07-02T16:34:26.777Z","phase":"Phase 2","brief_title":"Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma","source_id_and_acronym":"NCT05635162 - ZEBRA","lead_sponsor":"University College, London","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-06-12"},{"id":"d7b63745-b754-4312-8d12-7caa21ac459b","acronym":"BGB-A317-3111-10188-101","url":"https://clinicaltrials.gov/study/NCT04282018","created_at":"2021-01-18T20:47:22.139Z","updated_at":"2024-07-02T16:34:37.351Z","phase":"Phase 1/2","brief_title":"Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab","source_id_and_acronym":"NCT04282018 - BGB-A317-3111-10188-101","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188"],"overall_status":"Recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"51c7eecc-8aaa-40fe-a0b8-2cc5f7db6669","acronym":"","url":"https://clinicaltrials.gov/study/NCT05976763","created_at":"2023-08-04T17:10:02.415Z","updated_at":"2024-07-02T16:35:01.638Z","phase":"Phase 3","brief_title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT05976763","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 421","initiation":"Initiation: 09/08/2023","start_date":" 09/08/2023","primary_txt":" Primary completion: 08/31/2038","primary_completion_date":" 08/31/2038","study_txt":" Completion: 08/31/2038","study_completion_date":" 08/31/2038","last_update_posted":"2024-05-23"},{"id":"5331de4a-0a50-4497-ba7a-9fb515bc9e9b","acronym":"ZRCHOP-BGB-3111-2004-IIT","url":"https://clinicaltrials.gov/study/NCT05189197","created_at":"2022-01-12T14:53:41.245Z","updated_at":"2024-07-02T16:35:03.072Z","phase":"Phase 2","brief_title":"A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression","source_id_and_acronym":"NCT05189197 - ZRCHOP-BGB-3111-2004-IIT","lead_sponsor":"Fudan University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-05-17"},{"id":"0267f44d-4f9b-4560-bccb-ed43fad34538","acronym":"","url":"https://clinicaltrials.gov/study/NCT05681195","created_at":"2023-01-12T15:02:12.265Z","updated_at":"2024-07-02T16:35:05.915Z","phase":"Phase 2","brief_title":"Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas","source_id_and_acronym":"NCT05681195","lead_sponsor":"Baptist Health South Florida","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/25/2024","start_date":" 04/25/2024","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2024-05-06"},{"id":"04840d0e-2bde-4d03-ace9-5a9cdb7de1f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06367374","created_at":"2024-04-16T17:44:20.740Z","updated_at":"2024-07-02T16:35:09.492Z","phase":"Phase 2","brief_title":"MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL","source_id_and_acronym":"NCT06367374","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 02/28/2030","primary_completion_date":" 02/28/2030","study_txt":" Completion: 07/30/2030","study_completion_date":" 07/30/2030","last_update_posted":"2024-04-16"},{"id":"55894086-9f15-41f3-85e1-c28965784c6c","acronym":"CLL2-BZAG","url":"https://clinicaltrials.gov/study/NCT04515238","created_at":"2021-01-18T21:38:16.392Z","updated_at":"2024-07-02T16:35:13.069Z","phase":"Phase 2","brief_title":"Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL","source_id_and_acronym":"NCT04515238 - CLL2-BZAG","lead_sponsor":"German CLL Study Group","biomarkers":" BCL2 • PLCG2","pipe":"","alterations":" ","tags":["BCL2 • PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-03-25"},{"id":"31c8b0b8-4268-4696-a0fc-94d1c47df131","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168930","created_at":"2021-12-23T16:53:47.789Z","updated_at":"2024-07-02T16:35:24.052Z","phase":"Phase 2","brief_title":"Zanubrutinib and Venetoclax in CLL (ZANU-VEN)","source_id_and_acronym":"NCT05168930","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2028","study_completion_date":" 10/28/2028","last_update_posted":"2024-01-09"},{"id":"95429e19-93ae-4f9d-a017-2ea7e1fb48fb","acronym":"VIS","url":"https://clinicaltrials.gov/study/NCT05478512","created_at":"2022-07-28T13:54:33.388Z","updated_at":"2024-07-02T16:35:28.789Z","phase":"Phase 2","brief_title":"Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","source_id_and_acronym":"NCT05478512 - VIS","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-18"},{"id":"fffd03b5-1ee0-4f6d-864a-e1131f963859","acronym":"SEQUOIA","url":"https://clinicaltrials.gov/study/NCT03336333","created_at":"2021-01-17T17:29:22.685Z","updated_at":"2024-07-02T16:35:29.774Z","phase":"Phase 3","brief_title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","source_id_and_acronym":"NCT03336333 - SEQUOIA","lead_sponsor":"BeiGene","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 05/07/2021","primary_completion_date":" 05/07/2021","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-11-09"},{"id":"883c093f-d2f2-4bdb-a6df-2c4fb2930bc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890352","created_at":"2023-06-06T14:06:56.792Z","updated_at":"2024-07-02T16:35:34.556Z","phase":"Phase 2","brief_title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","source_id_and_acronym":"NCT05890352","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" MYC • BCL2 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Brukinsa (zanubrutinib) • Tazverik (tazemetostat) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2023-10-05"},{"id":"0466ada9-e74f-4425-8516-8215542bb544","acronym":"HOVON169CAD","url":"https://clinicaltrials.gov/study/NCT06067048","created_at":"2023-10-04T15:10:53.149Z","updated_at":"2024-07-02T16:35:34.755Z","phase":"Phase 2","brief_title":"Zanubrutinib in Primary Cold Agglutinin Disease","source_id_and_acronym":"NCT06067048 - HOVON169CAD","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2023-10-04"},{"id":"0e426c0f-3179-4559-b77c-71fde2532c31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05992597","created_at":"2023-08-15T19:10:14.676Z","updated_at":"2024-07-02T16:35:36.191Z","phase":"Phase 2","brief_title":"ZR2 Sequential Immunochemotherapy for Newly Treated MCL","source_id_and_acronym":"NCT05992597","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CCND1","pipe":"","alterations":" ","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Rituxan (rituximab) • lenalidomide • cytarabine • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-09-21"},{"id":"eac472e6-d913-41cb-be2a-e641cd27b30f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03824483","created_at":"2021-01-18T18:53:20.649Z","updated_at":"2024-07-02T16:35:36.679Z","phase":"Phase 2","brief_title":"Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","source_id_and_acronym":"NCT03824483","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 overexpression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 02/22/2019","start_date":" 02/22/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-18"},{"id":"1f95a638-2de9-4a52-9db6-9f7634c844f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896007","created_at":"2023-06-09T16:06:40.863Z","updated_at":"2024-07-02T16:35:38.187Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT","source_id_and_acronym":"NCT05896007","lead_sponsor":"Ruijin Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • temozolomide • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/13/2023","start_date":" 07/13/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-04"}]